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Abstract
Background: Although gastroesophageal reflux disease (GERD) is common in adolescents, the
burden of GERD on health-related quality of life (HRQOL) in adolescents has not been previously
evaluated. Therefore, the objective of the study was to examine the effect of GERD on HRQOL in
adolescents.
Methods: This international, 31-site, 8-week safety study randomized adolescents, aged 12 to 17
years inclusive, with GERD to receive esomeprazole 20 or 40 mg once daily. The Quality of Life in
Reflux and Dyspepsia questionnaire (QOLRAD), previously validated in adults, consists of 25
questions grouped into 5 domains: emotional distress, sleep disturbance, food/drink problems,
physical/social functioning, and vitality. The QOLRAD was administered at the baseline and week8 (final) visits.
Results: Of the 149 patients randomized, 134 completed the QOLRAD at baseline and final visits
and were eligible for analysis of their HRQOL data. Baseline QOLRAD scores indicated GERD had
a negative effect on the HRQOL of these adolescents, especially in the domains of vitality and
emotional distress, and problems with food/drink. At the final visit, mean scores for all 5 QOLRAD
domains improved significantly (P < .0001); change of scores (ie, delta) for all domains met or
exceeded the adult QOLRAD minimal clinically significant difference standard of 0.5 units.
Conclusion: GERD had a negative effect on QOL in adolescents. After esomeprazole treatment,
statistically and clinically significant improvements occurred in all domains of the QOLRAD for
these adolescents.
Trial Registration: D9614C00098; ClinicalTrials.gov Identifier NCT00241501
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Background
Gastroesophageal reflux disease (GERD) is recognized
increasingly as a common condition in adolescents [1].
Recent surveys of high school students show that at least
21% had significant GERD symptoms occurring a minimum of 1 time per month [2-4]. A survey conducted in
pediatric practices revealed that 5.2%, 5.0%, and 8.2% of
children and adolescents aged 10 to 17 years reported
experiencing heartburn, epigastric pain, and regurgitation,
respectively, in the previous week [5]. Moreover, in the
same time period, 27.9% of children aged 10 to 17 years
experienced abdominal pain, which may be a symptom of
GERD [5].
Findings of numerous studies have shown the negative
effect of GERD on health-related quality of life (HRQOL)
in adults; however, few studies have assessed the effect of
GERD on HRQOL in children and adolescents [6-15].
Although previously validated in adults [16], no data are
available on the validity and performance of the Quality
of Life in Reflux and Dyspepsia questionnaire (QOLRAD)
in adolescent GERD patients or on the burden of GERD
on HRQOL in adolescents.
Proton pump inhibitors (PPIs) have been recommended
as the most effective acid suppression therapy for adults
and children with GERD [17,18]. PPIs have been shown
to relieve or resolve GERD symptoms in most adult and
pediatric patients [19-23]. In Gold et al, we reported the
safety and efficacy of esomeprazole in treating the symptoms of GERD in adolescents [23]. In the current article,
we explore the effects of esomeprazole on QOL in the
adolescent patients from the Gold et al [23] study.

Methods
Study design
This international, phase 3, randomized study double
blinded for dose safety was conducted at 31 sites in Canada, France, Italy, and the United States (D9614C00098;
ClinicalTrials.gov Identifier NCT00241501). The study
was performed in accordance with the ethical principles
that have their origin in the Declaration of Helsinki and
that are consistent with ICH/Good Clinical Practice. The
study protocol was approved by the institutional review
boards, and all patients and their parents or guardians
provided written informed consent and assent before any
study procedure was conducted.

Patients were randomized 1:1 to receive esomeprazole
(Nexium®; AstraZeneca LP, Wilmington, DE) 20 or 40 mg
(no placebo control) orally once daily for 8 weeks. Esomeprazole was administered approximately 60 minutes
before breakfast. For patients unable to swallow capsules,
capsule contents could be mixed with 1 tablespoon of
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applesauce. Age-appropriate chewable antacid tablets
were provided for use as rescue medication.
Patients
Adolescents aged 12 to 17 years with a clinical diagnosis
of GERD based on medical history, physical examination,
any laboratory test results, and/or information from any
diagnostic testing (eg, pH monitoring, endoscopy,
biopsy) were eligible to participate in the study. The study
entry criteria were consistent with GERD diagnostic guidelines of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition [17]. Patients who
were infected with Helicobacter pylori (as documented by
the investigator using standard medical practice) but had
no evidence of active ulceration or recent gastrointestinal
bleeding were permitted at the discretion of the investigator. Postpubertal girls must have had a negative result on
their urine pregnancy tests at the screening and week-4
and -8 visits. Patients who had any gastrointestinal
pathology that required surgery, interfered with study participation, or potentially confounded study data were
excluded. Patients who had an acute or chronic illness or
condition (eg, pervasive developmental disorders, suspected abuse/neglect, recent trauma) that, in the opinion
of the investigator, placed the patient at risk for not completing the study or for potentially confounding the study
data were excluded. Patients could not have taken any PPI
within 14 days or H2-receptor antagonist or prokinetic
agent within 3 days of randomization. Patients also could
not use any study-restricted medications (eg, antiemetics,
bismuth-containing products, macrolide antibiotics, systemic steroids) on a continuous basis during the study.
Assessments
The QOLRAD, previously validated in adults [16], generally can be completed in approximately 12 to 15 minutes
and consists of 25 questions grouped into 5 domains:
emotional distress, sleep disturbance, food/drink problems, vitality, and physical/social functioning [16]. The
QOLRAD also has been translated and cross-culturally
validated into languages including French, German, Spanish, Italian, and French Canadian [24]. The QOLRAD was
administered at the randomization (baseline) and week-8
(final) visits. Responses were based on a 1-week recall
period and scored using a 7-point Likert response scale (1
= all of the time/a great deal; 7 = none of the time/none at
all); higher scores indicated better QOL. Administration
of the QOLRAD was standardized, and procedures were
used throughout the study to enhance patient compliance
in correctly completing the QOLRAD, such as quiet, privacy, and administration before other examinations.
Statistical analyses
Data from patients in both treatment groups were pooled
for analysis, and between-group comparisons were not
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made. Mean total scores and individual domain scores
were calculated at baseline and final visits and compared
using the paired t test. Mean change in score between
baseline and the final visit was considered clinically significant if 0.5 or more units [9]. This minimally clinically
significant change was established based on findings from
a previously conducted study assessing the reliability and
responsiveness to change over time of QOLRAD [9]. Missing item responses were replaced by the mean value of
completed items in that domain if 50% or more items in
that domain had been completed.
A post hoc assessment was conducted to compare baseline
QOLRAD scores from adolescents in this study with those
of adults in the previous QOLRAD validation study [16].
Though the methods and primary results of the QOLRAD
validation study were published previously, baseline
scores had not been reported previously [16]. Briefly, the
adult study was an international, multicenter psychometric evaluation in which 759 adult patients with chronic or
recurrent upper gastrointestinal symptoms completed the
QOLRAD. In the analysis presented here, mean baseline
QOLRAD scores from each of the 5 domains were calculated according to baseline heartburn severity (mild, moderate, severe). Differences in QOLRAD scores 0.5 or more
units between adult and adolescent patients were considered to be clinically significant.
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Results
Of the 149 patients randomized, more were girls (59.7%)
and white (83.2%) and the mean body mass index was
23.5 ± 4.9 kg/m2. Of these 149 patients, 134 completed
the QOLRAD at the baseline and final visits.
Baseline QOLRAD mean total scores (Figure 1) and mean
domain scores (Figure 2) indicated that GERD had a negative effect on the HRQOL of these patients compared
with normal adults. The QOLRAD domains most negatively affected by GERD were vitality, emotional distress,
and problems with food/drink (Figure 2).
QOLRAD mean total scores and mean domain scores
were improved significantly from baseline values after 8
weeks of esomeprazole therapy (P < .001) (Figures 1 and
2). Mean changes from baseline values in the QOLRAD
total and domain scores met or exceeded the established
adult QOLRAD minimum clinically significant difference
standard of 0.5 units (Table 1) [9].
At baseline, QOLRAD scores were similar in adolescents
and adults with mild heartburn (Table 2). However, the
differences in baseline QOLRAD scores in the domains of
emotional stress, sleep disturbance, and vitality between
adolescents and adults with moderate heartburn were
clinically significant (scores varied by ≥0.5 units). In addition, differences in baseline scores for the sleep disturbance and vitality domains between adolescents and
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Table 1: Mean changes in QOLRAD total and domain scores from baseline to final visit (n = 134).

QOLRAD Domain

Change in Mean Scoresa

Number of patients who significantly
improved, n (%)b

Number of patients who significantly
worsened, n (%)b

Emotional distress
Sleep disturbance
Food/drink problems
Vitality
Physical/social functioning
Total score

0.83
0.65
1.07
0.79
0.50
0.77

67 (50.0)
61 (45.5)
85 (63.4)
73 (54.5)
56 (41.8)
-

10 (7.5)
13 (9.7)
9 (6.7)
17 (12.7)
13 (9.7)
-

Abbreviation: QOLRAD, Quality of Life in Reflux and Dyspepsia questionnaire.
aP < .0001; bSignificant improvement and significant worsening defined as a change in score of 0.5 from baseline.

adults with severe heartburn were clinically significant
(Table 2).

Discussion
In this study, the burden of illness in adolescent patients
with GERD was measured by a disease-specific HRQOL
instrument, QOLRAD, previously validated in adults [16]
and used for the first time here in adolescents. Our results
demonstrated that GERD has a negative effect on HRQOL
in adolescents. These results are consistent with those of a
recent study by Tolia et al [15], which shows that, in children aged 2 to 18 years, GERD symptoms negatively affect
the QOL of children and their parents.
Because no placebo control group existed in the study, it
could not be determined how much of the change from
baseline in QOLRAD scores was attributable directly to
esomeprazole therapy. However, this study is the first to
show an improvement from baseline in HRQOL in all
QOLRAD domains (emotional distress, sleep disturbance,
food/drink problems, vitality, and physical/social functioning) in adolescents after treatment with a PPI in a clinical trial. In addition, the trial was a safety study, and
patients were randomized to different dose groups for this
purpose; it was not designed to be a comparative dosing
study of esomeprazole. Between-group assessments were
not made, and pooling of the data allowed for a better

estimate in comparison with QOLRAD data in adults.
Despite these study limitations, the findings are consistent
with improvement considered clinically significant (≥0.5
units) [9] and establish a benchmark for future QOL studies in children of different ages with GERD.
In adult patients, 4 weeks of treatment with the PPI
esomeprazole has been shown to significantly improve
QOLRAD scores from baseline [9,11,13,14]. In the study
reported by Talley et al [9], after 4 weeks of treatment with
esomeprazole 20 mg, esomeprazole 40 mg, or omeprazole 20 mg daily, changes from baseline in QOLRAD
domain scores ranged from 0.81 to 1.43. This unit change
for adult QOL was higher slightly than the changes from
baseline reported in this study in adolescents (Table 1)
[9]. Similarly, El-Dika et al [14] reported changes in
domain scores after 4 weeks of treatment with esomeprazole ranging from 1.3 to 2.0. However, in a study reported
by Pace et al [11], 4 weeks of treatment with esomeprazole
40 mg yielded domain changes ranging from 0.37 to 0.66,
slightly lower than those observed in our study (Table 1).
Moreover, studies in adults have shown that improved
QOL is maintained with esomeprazole treatment through
6 months [11,13].
QOLRAD scores from adults in other studies are difficult
to compare with scores from this study of adolescents

Table 2: Comparison of baseline QOLRAD scores in adolescents and adults based on heartburn severity.

Heartburn Severity at Baseline
Mild
QOLRAD Domain
Emotional distress
Sleep disturbance
Food/drink problems
Vitality
Physical/social functioning

Moderate

Severe

Adolescent

Adulta

Adolescent

Adulta

Adolescent

Adulta

5.4
5.4
4.6
5.1
5.9

5.2
5.4
5.0
5.0
6.0

4.9
5.0
4.3
4.5
5.5

4.1
4.4
4.0
3.9
5.1

3.5
4.8
3.8
4.0
4.7

3.5
3.7
3.5
3.2
4.3

Abbreviation: QOLRAD, Quality of Life in Reflux and Dyspepsia questionnaire.
aData from adults are derived from a previous study by Wiklund et al [16].
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because the change from baseline in QOLRAD scores in
sleep disturbance and food/drink problems has been
shown to be associated with baseline symptom severity
(none, mild, moderate, or severe); therefore, the largest
changes in QOLRAD scores occur in patients with more
severe symptoms at baseline [25]. An appropriate comparison of the effect of GERD on QOL between adults and
adolescents would be within the baseline level of symptom severity. Therefore, we compared baseline QOLRAD
scores according to baseline heartburn severity from adolescents in this study with those from adults in a separate
study [16]. For patients with moderate or severe heartburn, clinically significantly greater scores were observed
for adolescents compared with adults for the QOLRAD
domains of emotional distress (moderate heartburn
only), sleep disturbance, and vitality, indicating that moderate or severe heartburn has a more negative effect on
HRQOL in adults than adolescents. However, the effect of
mild heartburn on HRQOL in adolescents and adults is
similar.

Conclusion
Clinically significant improvements in HRQOL from
baseline values were observed in this 8-week trial of
esomeprazole treatment for GERD, which suggests that
esomeprazole treatment may reduce the negative effect of
GERD on HRQOL, particularly in the domains of vitality,
emotional distress, and problems with food/drink in adolescents.
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